Table IR15.D - 14.2.1.1.2.1.4.1
Summary of COVID-19* based on Adjudication Committee Assessments Starting after Randomization by Variant Groups
Per-Protocol Set

	Placebo (N=14164) n(%)	mRNA-1273 (N=14287) n(%)
Number of Subjects with COVID-19*, n (%)	769 (5.4)	56 (0.4)
Number of Events by Lineage, n (%)		
B.1	5 (<0.0)	-
B.1.1	1 (<0.0)	-
B.1.1.128	1 (<0.0)	-
B.1.1.186	2 (<0.0)	-
B.1.1.207	1 (<0.0)	-
B.1.1.222	8 (0.1)	-
B.1.1.316	1 (<0.0)	-
B.1.1.337	1 (<0.0)	-
B.1.1.432	1 (<0.0)	-
B.1.1.434	1 (<0.0)	-
B.1.1.519	2 (<0.0)	-
B.1.2	394 (2.8)	13 (0.1)
B.1.232	1 (<0.0)	-
B.1.234	6 (<0.0)	-
B.1.240	1 (<0.0)	-
B.1.243	23 (0.2)	1 (<0.0)
B.1.311	6 (<0.0)	-
B.1.349	1 (<0.0)	-
B.1.369	2 (<0.0)	-
B.1.375	1 (<0.0)	-

* with the censoring rules for efficacy analyses. COVID-19 case is based on eligible symptoms and positive RT-PCR within 14 days. If a subject had positive RT-PCR at pre-dose 2 visit (Day 29) without eligible symptoms with 14 days, or positive Elecsys at scheduled visits prior to becoming a COVID-19 case, the subject is censored at the date with positive RT-PCR or Elecsys.
**Haplotype is available without Lineage

Table IR15.D - 14.2.1.1.2.1.4.1
Summary of COVID-19* based on Adjudication Committee Assessments Starting after Randomization by Variant Groups
Per-Protocol Set

	Placebo (N=14164) n(%)	mRNA-1273 (N=14287) n(%)
Number of Events by Lineage, n (%) (Cont.)		
B.1.382	1 (<0.0)	-
B.1.396	1 (<0.0)	-
B.1.404	2 (<0.0)	-
B.1.427	6 (<0.0)	-
B.1.429	9 (0.1)	3 (<0.0)
B.1.517	2 (<0.0)	-
B.1.526.3	1 (<0.0)	-
B.1.544	2 (<0.0)	-
B.1.551	1 (<0.0)	-
B.1.561	5 (<0.0)	-
B.1.564	3 (<0.0)	-
B.1.587	8 (0.1)	-
B.1.595	2 (<0.0)	-
B.1.596	13 (0.1)	-
B.1.599	1 (<0.0)	-
B.1.605	1 (<0.0)	-
B.1.609	1 (<0.0)	-
P.1	1 (<0.0)	-
P.2	2 (<0.0)	-
R.1	3 (<0.0)	-
WILD TYPE	1 (<0.0)	-
None**	20 (0.1)	-

* with the censoring rules for efficacy analyses. COVID-19 case is based on eligible symptoms and positive RT-PCR within 14 days. If a subject had positive RT-PCR at pre-dose 2 visit (Day 29) without eligible symptoms with 14 days, or positive Elecsys at scheduled visits prior to becoming a COVID-19 case, the subject is censored at the date with positive RT-PCR or Elecsys.
**Haplotype is available without Lineage

Table IR15.D - 14.2.1.1.2.1.4.1
Summary of COVID-19* based on Adjudication Committee Assessments Starting after Randomization by Variant Groups
Per-Protocol Set

	Placebo (N=14164) n(%)	mRNA-1273 (N=14287) n(%)
Number of Events by Lineage, n (%) (Cont.)		
No Sequencing Data Available	224 (1.6)	39 (0.3)
By First Detected, n (%)		
Brazil	1 (<0.0)	-
P.1	1 (<0.0)	-
California	15 (0.1)	3 (<0.0)
B.1.427	6 (<0.0)	-
B.1.429	9 (0.1)	3 (<0.0)
Variant of Concern	16 (0.1)	3 (<0.0)
B.1.427	6 (<0.0)	-
B.1.429	9 (0.1)	3 (<0.0)
P.1	1 (<0.0)	-
Variant of Interest	2 (<0.0)	-
P.2	2 (<0.0)	-

* with the censoring rules for efficacy analyses. COVID-19 case is based on eligible symptoms and positive RT-PCR within 14 days. If a subject had positive RT-PCR at pre-dose 2 visit (Day 29) without eligible symptoms with 14 days, or positive Elecsys at scheduled visits prior to becoming a COVID-19 case, the subject is censored at the date with positive RT-PCR or Elecsys.
**Haplotype is available without Lineage